Lorviqua, known generically as lorlatinib, is a targeted therapy medication used in the treatment of non-small cell lung cancer (NSCLC). Specifically, it is designed for patients whose cancer has a specific genetic mutation in the anaplastic lymphoma kinase (ALK) gene and who have previously been treated with one or more ALK inhibitors. Lorviqua works by inhibiting the activity of the ALK protein, which can help to stop or slow the growth of cancer cells. It is an oral medication, making it convenient for patients to take. As with any cancer treatment, Lorviqua may cause side effects, and its use is typically guided by a healthcare professional specialized in oncology.